News | November 14, 2024
AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
Strokes are affecting approximately 1.8 million people annually
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Developed in consultation with clinicians and patients for an enhanced user experience
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
This license will enable Abbott to enhance access to this novel therapy to more patients across India
Coupled with Shea Butter, Cocoa Butter, and Mango Butter, the balm provides deep hydration, ensuring lips remain soft, smooth, and well-moisturized throughout the day
Subscribe To Our Newsletter & Stay Updated
